The BGI Group subsidiary said it plans to strengthen its R&D and instrument production, targeting a global sequencing market it expects to grow to $12.45 billion in 2022.
At the AGBT conference, MGI Tech showcased its technologies, while a Sanger Institute researcher presented results from a comparison between BGI and Illumina data.
Among the updates provided at the conference on Wednesday, Luminex discussed development and plans for the Verigene II system, and GenMark touted its ePlex test portfolio.
Paragon and MGI Tech — a unit of BGI — have signed a distribution deal for certain of their respective next-generation sequencing panels and sample prep products.
In a point-counterpoint in the Boston Globe, researchers discuss the potential of gene editing to prevent Lyme disease, but also the pitfalls of doing so.
